Top Markets
#1 Orochi Network Orochi Network +71.79%
#2 Bitway Bitway +26.98%
#3 Audiera Audiera +24.63%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.60%
#5 Pharos Pharos +15.97%
#6 SOON SOON +15.75%
#7 Cheems Token Cheems Token +14.21%
#8 Taiko Taiko +13.85%
#9 Manadia Manadia +13.47%
#10 ROLL ROLL +13.27%
Coin of the day
Orochi Network Orochi Network
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rang in Aktien #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Aktienkurs
$50.93
Marktkapitalisierung
$226.32B
Veränderung (1 Tag)
2.54%
Veränderung (1 Jahr)
-26.19%
Land
DK
Handel Novo Nordisk A/S (NVO)

Kategorie

Healthcare
P/B-Verhältnis für Novo Nordisk A/S (NVO)
P/B-Verhältnis zum July 2026 TTM: 6.99
Laut den neuesten Finanzberichten und dem Aktienkurs von Novo Nordisk A/S beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 6.99. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 19.38.
P/B-Verlauf für Novo Nordisk A/S von 2000 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 6.99 -6.12%
2025 7.45 -61.56%
2024 19.38 -34.02%
2023 29.37 15.39%
2022 25.45 6.65%
2021 23.87 51.77%
2020 15.72 -1.35%
2019 15.94 12.22%
2018 14.20 -14.34%
2017 16.58 16.48%
2016 14.23 -34.97%
2015 21.89 29.23%
2014 16.94 35.36%
2013 12.51 -0.67%
2012 12.60 26.42%
2011 9.97 0.88%
2010 9.88 77.44%
2009 5.57 9.91%
2008 5.07 -20.41%
2007 6.36 25.26%
2006 5.08 20.40%
2005 4.22 11.39%
2004 3.79 16.59%
2003 3.25 4.96%
2002 3.10 -47.14%
2001 5.86 -4.54%
2000 6.14 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.251 -10.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.1715 -68.95%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.065 -41.88%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3009 4.39%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
 34.7575 396.95%
US